Randomized, Multicentric, Partially Double-Blinded Placebo-Controlled Phase II Study for Examining the Influence of Ribavirin on the Initial Virological Response With Treatment of Peginterferon Alfa-2a (40KD) and Ribavirin With a Six Week Pretreatment-Phase of Ribavirin/Placebo or PEG-Interferon Monotherapy in Treatment Naïve Patients With Chronic Hepatitis C Virus Genotype 1 Infection
Phase of Trial: Phase II
Latest Information Update: 24 Aug 2016
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Roche
- 16 Jul 2010 Status changed from active, no longer recruiting to completed as reported by Roche record.
- 19 Dec 2009 Status changed from recruiting to active, no longer recruiting as reported by Roche
- 20 Jun 2009 Planned number of patients changed from 60 to 65 as reported by Roche.